How much is iTeos Therapeutics worth in 2026?

iTeos Therapeutics has a current valuation of N/A based on their PIPE round and secondary market data.

How much funding has iTeos Therapeutics raised?

iTeos Therapeutics has raised N/A in total funding across 1 funding rounds.

iTeos Therapeutics

Drug Discovery

iTeos Therapeutics valuation and funding history | Last updated: May 14, 2024 | 1 funding rounds

Current Valuation

N/A

As of May 14, 2024

Total Funding Raised

N/A

Across 1 round

Last Round

PIPE

$120.0M

Last Funding

May 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
May 14, 2024	PIPE	$120.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

iTeos Therapeutics is currently valued at N/A as of May 14, 2024.

Track iTeos Therapeutics Valuation Updates

Get notified when iTeos Therapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for iTeos Therapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock iTeos Therapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is iTeos Therapeutics Worth in 2026?

iTeos Therapeutics is a leading private company in the Drug Discovery sector. Track iTeos Therapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How iTeos Therapeutics Valuation is Determined

Private company valuations like iTeos Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.